UA will have a substantially more neutral trend than Revasc.
Last post for the day - this was indeed the outcome. So I think the MOA is pretty solid. And the result was nowhere near a fluke.
BTW - I think diabetes is the immediate path forward. I think there is a moderately good chance for approval based on ARISE alone. But I'll admit I don't have the FDA calibrated here.
Market Data 
Markets 
AI
